Dianthus Therapeutics Earnings Estimate
| DNTH Stock | 49.46 1.99 4.19% |
Dianthus Therapeutics Earnings Estimation Breakdown
The calculation of Dianthus Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Dianthus Therapeutics is estimated to be -0.9325 with the future projection ranging from a low of -1.185 to a high of -0.845. Please be aware that this consensus of annual earnings estimates for Dianthus Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.19 Lowest | Expected EPS | -0.84 Highest |
Dianthus Therapeutics Earnings Projection Consensus
Suppose the current estimates of Dianthus Therapeutics' value are higher than the current market price of the Dianthus Therapeutics stock. In this case, investors may conclude that Dianthus Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Dianthus Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 14 | 70.33% | -0.81 | -0.9325 | -3.5 |
Dianthus Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Dianthus Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Dianthus Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Dianthus Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Dianthus Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Dianthus Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Dianthus Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Dianthus Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Dianthus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-05 | 2025-09-30 | -0.55 | -0.97 | -0.42 | 76 | ||
2025-08-07 | 2025-06-30 | -0.53 | -0.88 | -0.35 | 66 | ||
2025-05-07 | 2025-03-31 | -0.71 | -0.82 | -0.11 | 15 | ||
2025-03-19 | 2024-12-31 | -0.76 | -0.81 | -0.05 | 6 | ||
2024-11-07 | 2024-09-30 | -0.59 | -0.72 | -0.13 | 22 | ||
2024-08-08 | 2024-06-30 | -0.55 | -0.51 | 0.04 | 7 | ||
2024-05-09 | 2024-03-31 | -0.44 | -0.54 | -0.1 | 22 | ||
2024-03-21 | 2023-12-31 | -1.01 | -0.71 | 0.3 | 29 | ||
2023-11-09 | 2023-09-30 | -0.56 | -3.78 | -3.22 | 575 | ||
2023-09-18 | 2023-06-30 | -3.04 | -0.8663 | 2.1737 | 71 | ||
2023-05-11 | 2023-03-31 | -0.4 | -0.47 | -0.07 | 17 | ||
2023-03-07 | 2022-12-31 | -0.2762 | -0.3 | -0.0238 | 8 | ||
2022-11-03 | 2022-09-30 | -0.29 | -0.27 | 0.02 | 6 | ||
2022-08-04 | 2022-06-30 | -0.34 | -0.29 | 0.05 | 14 | ||
2022-05-16 | 2022-03-31 | -0.3181 | -0.39 | -0.0719 | 22 | ||
2022-03-08 | 2021-12-31 | -0.3169 | -0.33 | -0.0131 | 4 | ||
2021-11-04 | 2021-09-30 | -0.3285 | -0.3 | 0.0285 | 8 | ||
2021-08-05 | 2021-06-30 | -0.3725 | -0.32 | 0.0525 | 14 | ||
2021-05-06 | 2021-03-31 | -0.388 | -0.36 | 0.028 | 7 | ||
2021-03-03 | 2020-12-31 | -0.388 | -0.38 | 0.008 | 2 | ||
2020-11-05 | 2020-09-30 | -0.43 | -0.37 | 0.06 | 13 | ||
2020-08-06 | 2020-06-30 | -0.54 | -0.48 | 0.06 | 11 | ||
2020-05-07 | 2020-03-31 | -0.6 | -0.51 | 0.09 | 15 | ||
2020-03-03 | 2019-12-31 | -0.58 | -0.59 | -0.01 | 1 | ||
2019-11-13 | 2019-09-30 | -0.53 | -0.54 | -0.01 | 1 | ||
2019-08-08 | 2019-06-30 | -0.49 | -0.48 | 0.01 | 2 | ||
2019-05-09 | 2019-03-31 | -0.55 | -0.44 | 0.11 | 20 | ||
2019-03-19 | 2018-12-31 | -0.53 | -0.5 | 0.03 | 5 | ||
2018-11-08 | 2018-09-30 | -0.67 | -0.49 | 0.18 | 26 | ||
2018-08-09 | 2018-06-30 | -1.13 | -3.13 | -2.0 | 176 | ||
2018-05-30 | 2018-03-31 | 0 | -4.45 | -4.45 | 0 | ||
2018-02-03 | 2017-12-31 | 0 | -1.03 | -1.03 | 0 | ||
2017-05-04 | 2017-03-31 | 0 | -0.15 | -0.15 | 0 |
About Dianthus Therapeutics Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Dianthus Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Dianthus Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Dianthus Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -157 M | -164.8 M | |
| Earnings Yield | (0.13) | (0.14) | |
| Price Earnings Ratio | (7.69) | (8.08) | |
| Price Earnings To Growth Ratio | 0.11 | 0.12 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is there potential for Biotechnology market expansion? Will Dianthus introduce new products? Factors like these will boost the valuation of Dianthus Therapeutics. Projected growth potential of Dianthus fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.50) | Revenue Per Share | Quarterly Revenue Growth (0.82) | Return On Assets | Return On Equity |
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Dianthus Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dianthus Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Dianthus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.